GEN-MKT-18-7897-A
Jan 26, 2018 | Biopharma, Blogs, Life Science Research, Proteomics, Technology | 0 comments
There’s no doubt about it, biopharma drug development is experiencing phenomenal growth and presents a variety of challenges not experienced in small molecule development. Some of these challenges are in the selective and sensitive quantitation of peptides and proteins in complex matrices. These large molecule analytes can suffer from matrix interferences, poor fragmentation and lack of quality unique peptides, or transitions compared to background, all which can affect the quality of analysis.
Traditional mass spectrometry (LC-MS/MS) assays continue to be highly effective for large molecule quantitation, but what if you need something more selective? What if you could easily ‘upgrade’ your already powerful mass spec? Thanks to advancements in mass spectrometry technology there is now an option that can be a game changer for peptide and protein quantitation workflows.
We are talking about the SelexION® Differential Mobility Separation (DMS) device. It offers a unique enhancement to your SCIEX mass spec, helping to remove sample interferences and separate isobaric peptide species, resulting in more sensitive and selective detection and quantitation of challenging large molecule targets.
Key Features of SelexION Technology for Peptide and Protein QuantitationUsing differential ion mobility spectroscopy (DMS) as an orthogonal dimension of separation prior to MS detection can provide many advantages:
Can provide enhanced specificity, selectivity, and sensitivity compared to LC-MS/MS alone
Do you want to know more? We thought you might, so we have worked on a library of tech notes to support you in your quest to achieve high performing peptide and protein quantitation workflows in drug discovery and development. Download the eBook and get access to technical papers, webinars, and so much more.
Find out about The Science Behind SelexION Differential Ion Mobility Technology and How SeleXION Addresses Your Biggest Analytical Challenges.
Download eBook >
It is no secret that (bio)pharmaceutical research and development is complex, both scientific and regulatory processes. Here is an overview of just some of the ways SCIEX is working to support these challenges.
In a recent webinar, available on demand, scientists Luiza Chrojan and Ryan Hylands from Pharmaron, provided insights into the deployment of capillary gel electrophoresis (CGE) within cell and gene therapy. Luiza and Ryan shared purity data on plasmids used for adeno-associated virus (AAV) manufacturing and data on AAV genome integrity, viral protein (VP) purity and VP ratios using the BioPhase 8800 system.
Last year, Technology Networks hosted two webinars that featured groundbreaking research utilizing SWATH DIA (data-independent acquisition) for exposomics and metabolomics. Researchers Dr. Vinicius Verri Hernandes from the University of Vienna and Dr. Cristina Balcells from Imperial College London (ICL) demonstrated how a DIA approach can be successfully implemented in small molecule analysis using the ZenoTOF 7600 system. Their innovative approaches highlight the potential of SWATH DIA to enhance the detection and analysis of chemical exposures and metabolites, paving the way for new insights into environmental health and disease mechanisms.
Posted by
You must be logged in to post a comment.
Share this post with your network